NEOS Neo Therapeutics Inc

NEOS INVESTOR ALERT: The Law Offices of Vincent Wong Launches Investigation of Neos Therapeutics, Inc. for Possible Securities Fraud Violations

NEW YORK--(BUSINESS WIRE)--

The Law Offices of Vincent Wong are investigating Neos Therapeutics, Inc. (NASDAQGM: NEOS) in relation to possible violations of federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/NEOS-Info-Request-Form-1342. There is no cost or obligation to you.

On October 19, 2015, Neos Therapeutics disclosed that the U.S. Food and Drug Administration has identified deficiencies in the Company’s new drug application for Cotempla XR-ODT that preclude discussion of labeling and marketing requirements at this time. Shares of Neos Therapeutics were down more than 23% on intraday trading on October 20, 2015. Then on August 11, 2016, Neos announced its financial results for the second quarter of 2016, reporting it had missed its earnings expectations by a significant $0.49 per share. Following this news, shares of Neos fell from a close of $8.57 per share on August 10, 2016 to a close of $7.27 per share on August 11, 2016. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/NEOS-Info-Request-Form-1342.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
30/09/2016

Underlying

NEOSNeo Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neo Therapeutics Inc

 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neo...

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at , or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help ...

March 12, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeuti...

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at , or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders...

March 10, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Sto...

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 – Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage ph...

February 10, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Con...

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website...

January 4, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agree...

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022  Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class prescription therapeutic...

December 10, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch